Gamgertamig
Based on 1 Customer Validation
Gamgertamig (OM336) is a bispecific T cell engager (TCE) antibody targeting B cell maturation antigen (BCMA) and CD3ε/δ. Gamgertamig exhibits potent antigen-dependent cytotoxicity and is capable of broadly depleting B cells and plasma cells. Gamgertamig binds with low affinity to CD3ε/δ on T cells (Kd = 34 nM) and with high affinity to BCMA on target cells (Kd = 0.65 nM), thereby specifically mediating cytotoxic killing of BCMA-positive target cells while reducing nonspecific T cell activation and cytokine release. Gamgertamig can be used for research on multiple myeloma and autoimmune diseases.
For research use only. We do not sell to patients.
- Purity : 99.32%
- CAS No.: 3038119-48-8
- Molecular Weight:145.607 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Ig(G4 - kappa_G4 - lambda2)
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
TNFRSF17/BCMA/CD269 & CD3E
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| NCI-H929 | EC50 |
0.10 nM
|
T-cell-dependent cellular cytotoxicity against BCMA-positive NCI-H929 cells co-cultured with human PBMCs at 10:1 E:T ratio incubated 48 hrs by One-Glo EX luciferase assay.
T-cell-dependent cellular cytotoxicity against BCMA-positive NCI-H929 cells co-cultured with human PBMCs at 10:1 E:T ratio incubated 48 hrs by One-Glo EX luciferase assay.
|
42619408 |
| Mino | EC50 |
0.16 nM
|
T-cell-dependent cellular cytotoxicity against BCMA-positive Mino cells co-cultured with human PBMCs at 10:1 E:T ratio incubated 48 hrs by One-Glo EX luciferase assay.
T-cell-dependent cellular cytotoxicity against BCMA-positive Mino cells co-cultured with human PBMCs at 10:1 E:T ratio incubated 48 hrs by One-Glo EX luciferase assay.
|
42619408 |
In Vitro
Gamgertamig (24-72 h) mediates potent, BCMA-dependent lysis of NCI-H929 and Mino cells, with EC50 values of 0.10 nM and 0.16 nM at 48 h, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:NCI-H929 and Mino cell lines, co-cultured with human PBMCs
-
Concentration:25 nM
-
Incubation Time:48 h
-
Result:Induced the release of IFNγ and IL-6, but the release levels were numerically lower compared to the teclistamab analog, indicating a profile of limited cytokine release.
Parmacokinetics
In Vivo
Gamgertamig (0.3-3 mg/kg; s.c.; once every 5 days for 3 doses) produces dose-dependent tumor growth inhibition in MM.1S xenograft tumors, with a mean tumor inhibition rate of 80% at 3 mg/kg[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:B-NDG (female, 7 weeks of age)[1]
-
Dosage:0.04 mg/kg, 0.2 mg/kg, 1 mg/kg
-
Administration:s.c.; every 5 days for two doses
-
Result:Mean tumor inhibition rates were 47%, 50%, and 95% at 0.04, 0.2, and 1 mg/kg, respectively.
Tumor regressions below the starting volume occurred in 1/10, 3/10, and 6/10 animals at these doses, respectively.
-
Animal Model:B-NDG (female, 7 weeks of age)[1]
-
Dosage:0.3 mg/kg, 1 mg/kg, 3 mg/kg
-
Administration:s.c.; every 5 days for three doses
-
Result:Mean tumor inhibition rates were 33%, 73%, and 80% at 0.3, 1, and 3 mg/kg, respectively.
Tumor regressions below the starting volume occurred in 4/10 and 3/10 animals at 1 mg/kg and 3 mg/kg, respectively.
-
Animal Model:rhesus monkey[1]
-
Dosage:0.5 mg/kg, 1.5 mg/kg, 4.5 mg/kg
-
Administration:s.c.; once weekly for 4 consecutive weeks; monitored until day 58
-
Result:Caused a sharp decline in peripheral blood B cell counts after the first dose, and maintained suppression for multiple weeks after dosing concluded, followed by dose-dependent recovery.
Significantly reduced the percentage of plasma cells in bone marrow smears.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
IgG4-kappa-lambda
Application
ELISA, FACS, Functional assay
Verified Bioactivity
Chemical Information
-
CAS No. 3038119-48-8
-
Appearance Liquid
-
Molecular Weight 145.607 kDa
-
Color Colorless to light yellow
-
SMILES
N/A
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (277 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Gamgertamig Related Classifications
HY-P991686 Related Classifications
Powered by Bioz